Company intelligence / Profile preview

AlgenScribe

Nice, Provence-Alpes-Côte d'Azur, Francealgenscribe.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

AlgenScribe is developing a proprietary genome-editing platform that enhances the efficiency and precision of CRISPR/Cas9-mediated gene editing. The company’s technology aims to overcome key limitations such as off-target effects and low homologous recombination rates. It is currently in pre-clinical development with collaborations underway to validate its approach in various disease models. No clinical results have been published yet.

Therapeutic areas: Rare Diseases
Modalities: Genome editing (CRISPR/Cas9-based)Gene therapyHomologous recombination enhancement
Industry: Biotech

Beyond the preview

Go deeper on AlgenScribe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlgenScribe.

Explore the full profile